|
| 37907723 | Computational immunogenomic approaches to predict response to cancer immunotherapies. | Nat Rev Clin Oncol | 2024 |
| 37907723 | Computational immunogenomic approaches to predict response to cancer immunotherapies. | Nat Rev Clin Oncol | 2024 |
| 36378549 | Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma. | Clin Cancer Res | 2023 |
| 36378549 | Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma. | Clin Cancer Res | 2023 |
| 37270644 | Lysophosphatidic acid modulates CD8 T cell immunosurveillance and metabolism to impair anti-tumor immunity. | Nat Commun | 2023 |
| 37197667 | <i>CTLA4</i> mRNA is downregulated by miR-155 in regulatory T cells, and reduced blood <i>CTLA4</i> levels are associated with poor prognosis in metastatic melanoma patients. | Front Immunol | 2023 |
| 37270644 | Lysophosphatidic acid modulates CD8 T cell immunosurveillance and metabolism to impair anti-tumor immunity. | Nat Commun | 2023 |
| 37197667 | <i>CTLA4</i> mRNA is downregulated by miR-155 in regulatory T cells, and reduced blood <i>CTLA4</i> levels are associated with poor prognosis in metastatic melanoma patients. | Front Immunol | 2023 |
| 34537899 | Adjuvant Therapy for Stage III Melanoma Without Immediate Completion Lymph Node Dissection. | Ann Surg Oncol | 2022 |
| 36098958 | Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes. | Cancer Discov | 2022 |
| 35637530 | Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma. | Genome Med | 2022 |
| 35565240 | BRAF Modulates Lipid Use and Accumulation. | Cancers (Basel) | 2022 |
| 35431929 | How Our Continuing Studies of the Pre-clinical Inbred Mouse Models of Mesothelioma Have Influenced the Development of New Therapies. | Front Pharmacol | 2022 |
| 36512357 | Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma. | JAMA Netw Open | 2022 |
| 35028137 | Circulating CD8<sup>+</sup> mucosal-associated invariant T cells correlate with improved treatment responses and overall survival in anti-PD-1-treated melanoma patients. | Clin Transl Immunology | 2022 |
| 35186441 | What's next in cancer immunotherapy? - The promise and challenges of neoantigen vaccination. | Oncoimmunology | 2022 |
| 34487023 | Profile of soluble factors in pleural effusions predict prognosis in mesothelioma. | Cancer Biomark | 2022 |
| 34942200 | Expression Differences in BCL2 Family Members between Uveal and Cutaneous Melanomas Account for Varying Sensitivity to BH3 Mimetics. | J Invest Dermatol | 2022 |
| 34537899 | Adjuvant Therapy for Stage III Melanoma Without Immediate Completion Lymph Node Dissection. | Ann Surg Oncol | 2022 |
| 35431929 | How Our Continuing Studies of the Pre-clinical Inbred Mouse Models of Mesothelioma Have Influenced the Development of New Therapies. | Front Pharmacol | 2022 |
| 35637530 | Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma. | Genome Med | 2022 |
| 35565240 | BRAF Modulates Lipid Use and Accumulation. | Cancers (Basel) | 2022 |
| 36512357 | Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma. | JAMA Netw Open | 2022 |
| 36098958 | Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes. | Cancer Discov | 2022 |
| 35186441 | What's next in cancer immunotherapy? - The promise and challenges of neoantigen vaccination. | Oncoimmunology | 2022 |
| 34942200 | Expression Differences in BCL2 Family Members between Uveal and Cutaneous Melanomas Account for Varying Sensitivity to BH3 Mimetics. | J Invest Dermatol | 2022 |
| 35028137 | Circulating CD8<sup>+</sup> mucosal-associated invariant T cells correlate with improved treatment responses and overall survival in anti-PD-1-treated melanoma patients. | Clin Transl Immunology | 2022 |
| 34487023 | Profile of soluble factors in pleural effusions predict prognosis in mesothelioma. | Cancer Biomark | 2022 |
| 32800877 | Melanocyte Precursors in the Hair Follicle Bulge of Repigmented Vitiligo Skin Are Controlled by RHO-GTPase, KCTD10, and CTNNB1 Signaling. | J Invest Dermatol | 2021 |
| 35590147 | Liquid biopsies for residual disease and recurrence. | Med | 2021 |
| 34285073 | Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies. | Proc Natl Acad Sci U S A | 2021 |
| 33581342 | The Current Lung Cancer Neoantigen Landscape and Implications for Therapy. | J Thorac Oncol | 2021 |
| 33509005 | A phase 1b clinical trial optimizing regulatory T cell depletion in combination with platinum-based chemotherapy in thoracic cancers. | Expert Rev Anticancer Ther | 2021 |
| 34089374 | Correction to: Tumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is used. | Cancer Immunol Immunother | 2021 |
| 34348236 | Melanoma Metastases to the Adrenal Gland Are Highly Resistant to Immune Checkpoint Inhibitors. | J Natl Compr Canc Netw | 2021 |
| 33087417 | Studying Immunotherapy Resistance in a Melanoma Autologous Humanized Mouse Xenograft. | Mol Cancer Res | 2021 |
| 33241424 | Avapritinib for Cutaneous Mastocytosis. | Acta Derm Venereol | 2021 |
| 32800877 | Melanocyte Precursors in the Hair Follicle Bulge of Repigmented Vitiligo Skin Are Controlled by RHO-GTPase, KCTD10, and CTNNB1 Signaling. | J Invest Dermatol | 2021 |
| 34451846 | A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine. | Pharmaceuticals (Basel) | 2021 |
| 34376578 | Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma. | Mol Cancer Ther | 2021 |
| 35590147 | Liquid biopsies for residual disease and recurrence. | Med | 2021 |
| 33509005 | A phase 1b clinical trial optimizing regulatory T cell depletion in combination with platinum-based chemotherapy in thoracic cancers. | Expert Rev Anticancer Ther | 2021 |
| 33581342 | The Current Lung Cancer Neoantigen Landscape and Implications for Therapy. | J Thorac Oncol | 2021 |
| 34376578 | Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma. | Mol Cancer Ther | 2021 |
| 34451846 | A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine. | Pharmaceuticals (Basel) | 2021 |
| 34348236 | Melanoma Metastases to the Adrenal Gland Are Highly Resistant to Immune Checkpoint Inhibitors. | J Natl Compr Canc Netw | 2021 |
| 34089374 | Correction to: Tumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is used. | Cancer Immunol Immunother | 2021 |
| 34285073 | Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies. | Proc Natl Acad Sci U S A | 2021 |
| 33087417 | Studying Immunotherapy Resistance in a Melanoma Autologous Humanized Mouse Xenograft. | Mol Cancer Res | 2021 |
| 33241424 | Avapritinib for Cutaneous Mastocytosis. | Acta Derm Venereol | 2021 |